Ubrogepant
Brand name: Ubrelvy
Rank #157 of 500 drugs by total cost
$100.6M
Total Cost
75,781
Total Claims
$100.6M
Total Cost
2,545
Prescribers
$1,327
Cost per Claim
8,589
Beneficiaries
78,499
30-Day Fills
$40K
Avg Cost/Provider
30
Avg Claims/Provider
About Ubrogepant
Ubrogepant (sold as Ubrelvy) was prescribed 75,781 times by 2,545 Medicare Part D providers in 2023, costing the program $100.6M. At $1,327 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 154 | Divalproex Sodium (Divalproex Sodium) | $103.4M | 1,921,840 |
| 155 | Nilotinib Hcl (Tasigna) | $100.9M | 6,308 |
| 156 | Quetiapine Fumarate (Quetiapine Fumarate) | $100.9M | 3,820,737 |
| 157 | Ubrogepant (Ubrelvy) | $100.6M | 75,781 |
| 158 | Darunavir/Cobicistat (Prezcobix) | $99.7M | 38,374 |
| 159 | Tocilizumab (Actemra) | $99.5M | 24,891 |
| 160 | Omalizumab (Xolair) | $98.9M | 30,451 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology